| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 12, 2004
From the Heart Research Institute, Sydney (S.J.N., B.C., K.-A.R., P.J.B., S.B.); the Department of Medicine, University of Adelaide, Adelaide (S.J.N.); the Howard Florey Institute, University of Melbourne, Melbourne (G.J.D., G.R.D.); the Department of Medicine, University of Sydney, Sydney (P.J.B.); and the Department of Pathology, University of Sydney, Sydney (S.B.), Australia. * To whom correspondence should be addressed. E-mail: p.barter{at}hri.org.au.
Background--HDLs have antiinflammatory and antioxidant properties in vitro. This study investigates these properties in vivo. Methods and Results--Chow-fed, normocholesterolemic New Zealand White rabbits received a daily infusion of (1) saline, (2) reconstituted HDL (rHDL) containing 25 mg apolipoprotein (apo) A-I and 50 mg of either 1-palmitoyl-2-linoleoyl phosphatidylcholine (PLPC) or 1,2-dipalmitoyl phosphatidylcholine (DPPC), (3) 25 mg lipid-free apoA-I, or (4) 50 mg of either PLPC-small unilamellar vesicles (SUVs) or DPPC-SUVs on each of 3 consecutive days. Nonocclusive carotid periarterial collars were implanted after the second dose of treatment. Forty-eight hours after insertion of the collars, the arteries were removed and analyzed for the presence of reactive oxygen species, the infiltration of neutrophils, and the expression of adhesion proteins and chemokines. Insertion of the periarterial collar induced a 4.1-fold increase in presence of vascular wall reactive oxygen species. This effect was completely abolished in the animals infused with rHDL. The periarterial collar was associated with a dense infiltration of the arterial wall by polymorphonuclear leukocytes. This infiltration was inhibited by 73% to 94% in the animals infused with rHDL, by 75% in the animals infused with lipid-free apoA-I, and by 51% to 65% in animals infused with SUVs. There were no significant differences between the effects of PLPC and DPPC in either the rHDL or SUVs. Endothelial expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1 was also increased by the collar insertion and inhibited by rHDL, lipid-free apoA-I, and, to a lesser extent, also by the SUVs. Conclusions--Infusion of rHDL, apoA-I, and phospholipid-SUVs inhibits the early pro-oxidant and proinflammatory changes induced by a periarterial collar in normocholesterolemic rabbits.
Revised on November 15, 2004
Accepted on December 13, 2004
Reconstituted High-Density Lipoproteins Inhibit the Acute Pro-Oxidant and Proinflammatory Vascular Changes Induced by a Periarterial Collar in Normocholesterolemic Rabbits
Stephen J. Nicholls MB BS, PhD, FRACP,
This article has been cited by other articles:
![]() |
A. Zerrad-Saadi, P. Therond, S. Chantepie, M. Couturier, K.-A. Rye, M. J. Chapman, and A. Kontush HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2169 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.C.Y. McGrath, X.H. Li, R. Puranik, E.C. Liong, J.T.M. Tan, V.M. Dy, B.A. DiBartolo, P.J. Barter, K.A. Rye, and A.K. Heather Role of 3{beta}-Hydroxysteroid-{Delta}24 Reductase in Mediating Antiinflammatory Effects of High-Density Lipoproteins in Endothelial Cells Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 877 - 882. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Frias, R. W. James, C. Gerber-Wicht, and U. Lang Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate Cardiovasc Res, May 1, 2009; 82(2): 313 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sattler and B. Levkau Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection Cardiovasc Res, May 1, 2009; 82(2): 201 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Shao and J. W. Heinecke HDL, lipid peroxidation, and atherosclerosis J. Lipid Res., April 1, 2009; 50(4): 599 - 601. [Full Text] [PDF] |
||||
![]() |
K.-A. Rye, C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter The metabolism and anti-atherogenic properties of HDL J. Lipid Res., April 1, 2009; 50(Supplement): S195 - S200. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Patel, B. G. Drew, S. Nakhla, S. J. Duffy, A. J. Murphy, P. J. Barter, K.-A. Rye, J. Chin-Dusting, A. Hoang, D. Sviridov, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol., March 17, 2009; 53(11): 962 - 971. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. El Harchaoui, B. J. Arsenault, R. Franssen, J.-P. Despres, G. K. Hovingh, E. S.G. Stroes, J. D. Otvos, N. J. Wareham, J. J.P. Kastelein, K.-T. Khaw, et al. High-Density Lipoprotein Particle Size and Concentration and Coronary Risk Ann Intern Med, January 20, 2009; 150(2): 84 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mackness and M. Mackness High-density lipoprotein: why all the fuss? Ann Clin Biochem, January 1, 2009; 46(1): 5 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A. M. Dart Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque Circ. Res., November 7, 2008; 103(10): 1084 - 1091. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-A. Rye and P. J. Barter Antiinflammatory Actions of HDL: A New Insight Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1890 - 1891. [Full Text] [PDF] |
||||
![]() |
A. J. Murphy, K. J. Woollard, A. Hoang, N. Mukhamedova, R. A. Stirzaker, S. P.A. McCormick, A. T. Remaley, D. Sviridov, and J. Chin-Dusting High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 2071 - 2077. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, S. Bao, D. Lai, R. W. Rapkins, and M. C. Gillies Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas Diabetes, April 1, 2008; 57(4): 1026 - 1033. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Q. Zhao and B. G. Brown ApoA-I(Milano)/phospholipid complex: clinical implications of dose-response studies in rabbit atherosclerosis with intravascular ultrasound and magnetic resonance imaging. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1110 - 1111. [Full Text] [PDF] |
||||
![]() |
M. Gomaraschi, L. Calabresi, G. Rossoni, S. Iametti, G. Franceschini, J. A. Stonik, and A. T. Remaley Anti-Inflammatory and Cardioprotective Activities of Synthetic High-Density Lipoprotein Containing Apolipoprotein A-I Mimetic Peptides J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 776 - 783. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Parastatidis, L. Thomson, D. M. Fries, R. E. Moore, J. Tohyama, X. Fu, S. L. Hazen, H. F.G. Heijnen, M. K. Dennehy, D. C. Liebler, et al. Increased Protein Nitration Burden in the Atherosclerotic Lesions and Plasma of Apolipoprotein A-I Deficient Mice Circ. Res., August 17, 2007; 101(4): 368 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Birjmohun, S. I. van Leuven, J. H.M. Levels, C. van 't Veer, J. A. Kuivenhoven, J. C.M. Meijers, M. Levi, J. J.P. Kastelein, T. van der Poll, and E. S.G. Stroes High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1153 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lesnik and M. J. Chapman A new dimension in the vasculoprotective function of HDL: progenitor-mediated endothelium repair. Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 965 - 967. [Full Text] [PDF] |
||||
![]() |
P. Kee, D. Caiazza, K.-A. Rye, P.H.R. Barrett, L.A. Morehouse, and P.J. Barter Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 884 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 706 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Hovingh, B. A. Hutten, A. G. Holleboom, W. Petersen, P. Rol, A. Stalenhoef, A. H. Zwinderman, E. de Groot, J. J.P. Kastelein MD, and J. A. Kuivenhoven Compromised LCAT Function Is Associated With Increased Atherosclerosis Circulation, August 9, 2005; 112(6): 879 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.J. Barter Cardioprotective Effects of High-Density Lipoproteins: The Evidence Strengthens Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1305 - 1306. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |